Phase II study of oral S‐1 for treatment of metastatic colorectal carcinoma

@article{Shirao2004PhaseIS,
  title={Phase II study of oral S‐1 for treatment of metastatic colorectal carcinoma},
  author={Kuniaki Shirao and Atsushi Ohtsu and Hideho Takada and Yasushi Mitachi and Kosei Hirakawa and Noboru Horikoshi and Takeshi Okamura and Koichi Hirata and Soh Saitoh and Hiroharu Isomoto and Atsushi Satoh},
  journal={Cancer},
  year={2004},
  volume={100}
}
The goal of the current study was to evaluate the objective response rate and toxicity associated with the oral fluoropyrimidine S‐1 (a combination of tegafur, 5‐chloro‐2,4‐dihydroxypyridine, and potassium oxonate) in patients with previously untreated metastatic colorectal carcinoma. 

Phase I trial of neoadjuvant concurrent chemoradiotherapy with S-1 and weekly irinotecan in locally advanced rectal cancer.

  • H. ChoiN. Kim J. Ahn
  • Medicine
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • 2008

An early phase II trial of S-1 in Japanese patients with cytokine-refractory metastatic renal cell carcinoma

TLDR
S-1 is active and well tolerated for the treatment of cytokine-refractory metastatic RCC and should be continued until disease progression, unacceptable toxicity, or withdrawal of consent.

A late phase II study of S-1 for metastatic pancreatic cancer

TLDR
The major adverse events were anorexia, fatigue, hemoglobin reduction, nausea and pigmentation change, although most were tolerable and reversible and the condition resolved with anticoagulant therapy.

A pilot study of oxaliplatin with oral S-1 as second-line chemotherapy for patients with recurrent adenocarcimona of the uterine cervix

TLDR
SOX therapy is useful for the treatment of recurrent adenocarcinoma of the uterine cervix, having a promising antitumor effect and minimal adverse effects, and it is suggested that SOX therapy may contribute to improving the prognosis.

Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer

  • W. KoizumiN. Boku Y. Okada
  • Medicine
    Annals of oncology : official journal of the European Society for Medical Oncology
  • 2010
TLDR
S-1 combined with LV therapy demonstrated promising efficacy and acceptable safety in chemotherapy-naive patients with mCRC without the concurrent use of irinotecan, oxaliplatin, or molecular-targeted drugs.

Phase II study of S‐1 plus leucovorin in patients with metastatic colorectal cancer: Regimen of 1 week on, 1 week off

TLDR
A phase II study of S‐1 plus leucovorin given in a 4‐week schedule for patients with untreated metastatic colorectal cancer showed that the combination was effective, but grade 3 toxicities occurred at a relatively high rate.

Phase II study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer.

A phase II study of S-1, oxaliplatin, oral leucovorin, and bevacizumab combination therapy (SOLA) in patients with unresectable metastatic colorectal cancer

TLDR
The SOLA therapy showed excellent efficacy and tolerable toxicities except for peripheral sensory neuropathy in patients with mCRC, and is a promising candidate regimen to be compared with FOLFOX plus bevacizumab in a future phase III trial.

Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer.

  • A. GotoY. Yamada K. Shirao
  • Medicine
    Annals of oncology : official journal of the European Society for Medical Oncology
  • 2006
TLDR
It is suggested that combined treatment with S-1 and irinotecan is a promising regimen, offering benefits in terms of safety and survival as compared with conventional regimens in patients with advanced colorectal cancer.

Efficacy of S-1 in colorectal cancer

TLDR
This review aims to provide an evidence-based update of clinical trials that have investigated the clinical efficacy, adverse-event profile, dosage and administration of S-1, given alone or in combination with conventional chemotherapeutics and new target-oriented drugs, in the management of colorectal cancer.
...

References

SHOWING 1-10 OF 44 REFERENCES

Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma

TLDR
It is suggested that S-1 achieves similar responses to those of infusional 5-FU plus leucovorin and shows the potential of another biochemical modulation with easily manageable toxicity.

Phase II Study of S-1, a Novel Oral Derivative of 5-Fluorouracil, in Advanced Gastric Cancer

TLDR
This oral treatment is suitable for outpatients because of its mild toxicity and further therapeutic benefits are likely to be obtained by combining S-1 with other chemotherapeutic agents.

Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group.

TLDR
S-1 is effective against advanced gastric cancer and this oral treatment is suitable for outpatients because of its mild toxicity and further therapeutic benefits are likely to be obtained by combining S-1 with other chemotherapeutic agents.

An Early Phase II Study of Oral S-1, a Newly Developed 5-Fluorouracil Derivative for Advanced and Recurrent Gastrointestinal Cancers

TLDR
The antineoplastic effect of S-1, an antitumor agent developed, based on the biochemical modulation of FT by 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate (Oxo), in a molar ratio of 1:0.4:1 is considered to have positive effects in patients with advanced gastrointestinal cancer.

EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer

TLDR
S-1 is active in advanced colorectal cancer, but in order to establish a safer dose the drug should be subject to further investigations, and the dose was reduced by amendment during the study because of a higher than expected number of severe adverse drug reactions.

[Late phase II study of S-1 in patients with advanced head and neck cancer].

TLDR
It is concluded that S-1 is an active agent for the treatment of advanced/recurrent head and neck cancer.

Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug.

  • K. HirataN. Horikoshi T. Shirasaka
  • Medicine, Chemistry
    Clinical cancer research : an official journal of the American Association for Cancer Research
  • 1999
TLDR
S-1 may improve patients' quality of life because the pharmacokinetics of orally administered S-1 is almost similar to that of continuous i.v. infusion of 5-FU, it is concluded.

Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review.

TLDR
A review of the literature on three recent prodrugs of 5-FU, i.e., capecitabine, UFT (ftorafur [FTO] plus uracil), and S-1 (FTO plus 5-chloro-2,4-dihydroxypyridine plus potassium oxonate), focusing on antitumor activity and toxicity are presented.

Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.

  • E. Van CutsemC. Twelves P. Harper
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2001
TLDR
Oral capecitabine achieved an at least equivalent efficacy compared with IV 5-FU/LV as first-line treatment for metastatic colorectal cancer and demonstrated clinically meaningful safety advantages and the convenience of an oral agent.